The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
=== ColdFusion MX 7 === With the release of ColdFusion 7.0 on February 7, 2005, the naming convention was amended, rendering the product name "Macromedia ColdFusion MX 7" (the codename for CFMX7 was "Blackstone"). CFMX 7 added Flash-based and XForms-based web forms, and a report builder that output in Adobe PDF as well as FlashPaper, RTF and Excel. The Adobe PDF output is also available as a wrapper to any HTML page, converting that page to a quality printable document. The enterprise edition also added Gateways. These provide interaction with non-HTTP request services such as IM Services, SMS, Directory Watchers, and an asynchronous execution. XML support was boosted in this version to include native schema checking. ColdFusion MX 7.0.1 (codename "Merrimack") added support for Mac OS X, improvements to Flash forms, RTF support for CFReport, the new CFCPRoxy feature for Java/CFC integration, and more. ColdFusion MX 7.0.2 (codenamed "Mystic") included advanced features for working with Adobe Flex 2 as well as more improvements for the CF Report Builder.
=== 2018–present: The feud reignites === The peace between the two rappers found itself to be short-lived as 50 Cent would reignite the feud in 2015 when Ja Rule gave a feedback to a social follower via Twitter over a similar feud between Meek Mill and Drake. Enraged, 50 Cent later responded with photos and comments via Instagram, only siding with Drake. The feud would fully resurface two years later when 50 Cent mocked Ja Rule's involvement in that year's ill-fated Fyre Festival in which numerous concertgoers were scammed in a poorly conceived event based on Ja Rule's business relationship with fraudster Billy McFarland. Jackson would further continue reigniting tensions on January 18, 2018; when he would once again attack Ja Rule on Big Boy's Neighborhood during an interview. Ja Rule immediately responded to 50 Cent's comments on twitter the very next day. Further adding to the hostility; Jackson would prank Ja Rule in October 2018 by purchasing 200 discounted front-row tickets for an upcoming show of his in Arlington, Texas for a total of US$3,000 via Groupon. Jackson later confirmed on social media that he bought the tickets with the express intention of forcing Ja Rule to perform in front of rows of empty seats. Tensions would briefly reignite between Eminem and Ja Rule as he would attack him on the track "The Ringer" from his 2018 album Kamikaze. During Eminem's followup response to Machine Gun Kelly's diss track "Rap Devil", he included several lines claiming to have taken part in ending the careers of both Ja Rule and Benzino on Killshot.
High-intensity pulsed electric fields are being used as an alternative to heat pasteurization in fruit juices. Heat treatments sometimes fail to make a quality, microbiologically stable product. However, it was found that processing with high-intensity pulsed electric fields (PEF) can be applied to fruit juices to provide a shelf-stable and safe product. In addition, it was found that pulsed electric fields provide a fresh-like product with high nutritional value. Pulsed electric field processing is a type of nonthermal method for food preservation. Pulsed electric fields use short pulses of electricity to inactivate microbes. In addition, the use of PEF results in minimal detrimental effects on the quality of the food. PEFs kill microorganisms and provide better maintenance of the original colour, flavour, and nutritional value of the food as compared to heat treatments. This method of preservation works by placing two electrodes between liquid juices, then applying high-voltage pulses for microseconds to milliseconds. The high-voltage pulses have an intensity in the range of 10 to 80 kV/cm. The processing time of the juice is calculated by multiplying the number of pulses by the effective pulse duration. The high voltage of the pulses produces an electric field that results in the inactivation of microbes that may be present in the juice. The PEF temperatures are below the temperatures used in thermal processing. After the high-voltage treatment, the juice is aseptically packaged and refrigerated.
Sources: en.wikipedia.org
Synthesis of RNA typically occurs in the cell nucleus and is usually catalyzed by an enzyme—RNA polymerase—using DNA as a template, a process known as transcription. Initiation of transcription begins with the binding of the enzyme to a promoter sequence in the DNA (usually found "upstream" of a gene). The DNA double helix is unwound by the helicase activity of the enzyme. The enzyme then progresses along the template strand in the 3' to 5' direction, synthesizing a complementary RNA molecule with elongation occurring in the 5' to 3' direction. The DNA sequence also dictates where termination of RNA synthesis will occur. Primary transcript RNAs are often modified by enzymes after transcription. For example, a poly(A) tail and a 5' cap are added to eukaryotic pre-mRNA and introns are removed by the spliceosome. There are also a number of RNA-dependent RNA polymerases that use RNA as their template for synthesis of a new strand of RNA. For instance, a number of RNA viruses (such as poliovirus) use this type of enzyme to replicate their genetic material. Also, RNA-dependent RNA polymerase is part of the RNA interference pathway in many organisms.
One study reviewed the relative diagnostic value of enzyme and bicarbonate concentrations compared with enzyme output in 363 secretin-CCK tests. The investigators also evaluated the requirement for perfusion markers to accurately quantify volume, and the validity of a shortened sampling time (first 20 minutes). Only 60 percent of volume was recovered with the duodenal aspiration tube, suggesting that marker perfusion to correct for distal loss of secretion is important to accurately quantify volume. Using a trypsin output <50 U/kg/h as the reference standard, measurement of enzyme concentration alone misclassified approximately 10 percent of patients. Use of a shortened collection time misclassified approximately 4 percent of patients. The authors concluded that this was an unacceptably high rate of misclassification and that the standard prolonged collection of fluid using a perfusion marker must be performed to accurately measure exocrine function.
In patients with familial hyperaldosteronism type 1, there is a genetic crossover between specific regions of the CYP11B1 and CYP11B2 genes. This crossover results in the expression of an additional gene in the zona fasciculata, which is regulated by ACTH. The additional gene plays a role in synthesizing 18-hydroxycortisol by 18-hydroxylation of cortisol. This gene also plays a role in the biosynthesis of aldosterone and 18-oxocortisol. Cortisol 18-Hydroxycorticosterone 18-Oxocortisol Aldosterone synthase Steroid 11β-hydroxylase 6β-Hydroxycortisol
Collagen () is the main structural protein in the extracellular matrix of the connective tissues of many animals. It is the most abundant protein in mammals, making up 25% to 35% of protein content. Amino acids are bound together to form a triple helix of elongated fibril known as a collagen helix. It is mostly found in cartilage, bones, tendons, ligaments, and skin. Vitamin C is vital for collagen synthesis. Depending on the degree of mineralization, collagen tissues may be rigid (bone) or compliant (tendon) or have a gradient from rigid to compliant (cartilage). Collagen is also abundant in corneas, blood vessels, the gut, intervertebral discs, and dentin. In muscle tissue, it serves as a major component of the endomysium. Collagen constitutes 1% to 2% of muscle tissue and 6% by weight of skeletal muscle. The fibroblast is the most common cell creating collagen in animals. Collagen is used in numerous food products, such as in gelatin employed to thicken or flavor a food matrix. Although marketed as a dietary supplement and skincare product, there is little evidence it is beneficial for skin health. In biomaterials used in medicine, collagen has useful properties for artificial skin and healing of severe burns and wounds.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.